N-cyclopentyl-2-methoxyacetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-cyclopentyl-2-methoxyacetamide
• 化学式: C₈H₁₅NO₂
• mdl: MFCD01008124
• 分子量: 157.21
• InChiKey: BLMAIVKQGZKSBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS DE PIRROLIDINE SUBSTITUÉS PAR LA PYRIMIDINE, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014170197A1

  公开（公告）日：2014-10-23

  The invention relates to new pyrrolidine derivatives of the formula (I), wherein R1 to R3, Ar, L T and n are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及到新的吡咯烷衍生物，其化学式为（I），其中R1到R3、Ar、LT和n如描述和索赔中所定义，其用作药物，用于其治疗用途的方法以及含有它们的药物组合物。
• 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis
  申请人：Tsubouchi Hidetsugu

  公开号：US20080119478A1

  公开（公告）日：2008-05-22

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and —(CH2) n R2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种由下述通式（1）表示的2,3-二氢-6-硝基咪唑[2,1-b]噁唑化合物： 在上述式（1）中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R1和—(CH2)nR2可以与相邻的碳原子形成如下式（30）所示的螺环，其中，在下式中，RRR代表可能在哌啶环上具有取代基的哌啶基： （30）且R2代表苯并噻唑氧基、喹啉氧基、吡啶氧基或类似基团。该化合物对结核分枝杆菌、多重耐药结核分枝杆菌和非典型酸杆菌具有优异的杀菌作用。
• NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS
  申请人：Capet Marc

  公开号：US20100249187A1

  公开（公告）日：2010-09-30

  The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.

  本发明涉及具有拟激活神经酰胺-1-磷酸（S1P）受体活性的新化合物（I）的配方，其制备过程以及作为免疫抑制剂的用途。本发明还涉及含有这些化合物的制药组合物以及使用这些化合物治疗/预防免疫介导的疾病和情况或炎症性疾病和情况的用途。
• Urea compounds and their use as enzyme inhibitors
  申请人：BIAL-PORTELA & CA, S.A.

  公开号：US10023541B2

  公开（公告）日：2018-07-17

  A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

  具有以下结构的化合物 或其药学上可接受的盐或衍生物。多发性硬化症、脊髓损伤、帕金森病、左旋多巴诱发的运动障碍、亨廷顿氏病、吉尔-德-图雷特综合征、迟发性运动障碍、肌张力障碍、肌萎缩性脊髓侧索硬化症、阿尔茨海默氏症、癫痫、精神分裂症、颅内压增高、颅内压增高和颅内压增高、癫痫、精神分裂症、焦虑、抑郁、失眠、恶心、呕吐、酒精紊乱、药物成瘾（如鸦片制剂、尼古丁、可卡因、酒精和精神兴奋剂）、高血压、循环休克、心肌再灌注损伤、动脉粥样硬化、哮喘、青光眼、视网膜病变、癌症、炎症性肠病、急慢性肝病（如肝炎和肝硬化）、关节炎和骨质疏松症。
• AMINOPYRONES AND THEIR USE AS ATM INHIBITORS
  申请人：Kudos Pharmaceuticals Limited

  公开号：EP1654257B1

  公开（公告）日：2010-03-17